Losses
-€676,707 in three years
Every financial year from 2023 to 2025 closed with a loss. 2023 was the heaviest.
ImmuneSpec
Lifetime
3 annual accounts with figures on one time axispeak €883,559 (2025)
€883,559▲ 26.8%
lowest -€397,068 (2023)
-€201,723▼ €123,806
peak €2.6m (2025)
€2.6m▲ 12.7%
€896,755▲ 6.9%
peak 5.7 FTE (2025)
5.7 FTE▲ 67.6%
Board10 names since 2023
3 directors and 2 others
Owners2 names in the annual accounts
36.84% and 1 other
Documentsfilings and deeds
08-06-202653 days before the deadline
2025abbreviated format
Gross margin from €696,858 to €883,559Loss of €201,723Staff from 3.4 FTE to 5.7 FTECapital increase of €500,060 24-03Equity from €2.3m to €2.6mCash from €113,328 to €191,854
Key points
from the 2025 annual accountsTurnover
≈ €2.1m estimated
The abbreviated format states no turnover.
Staff
6 employees on 31-12-2025
In 2025, 4 people joined and 2 left.
Starting capital
€15,000
At the same address
10 companies
Public support
€540,996 awarded from 2023 to 2025
Flemish support, mostly Ontwikkelingsproject.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 2,150 companies had the same profile as ImmuneSpec has now. Each dot stands for 6 companies, two years later.
91.5%
were still trading
6.0%
stopped another way
2.2%
went bankrupt
Another 0.2% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 2,150 companies, not a prediction for ImmuneSpec. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director, , since 14-03-2023
Director, since 06-11-2023
Director, , since 21-12-2023
- 38.38%equity €28.5m (2026) · 31-03-2026 annual accounts of
- 26.17%equity €5.2m (2025) · 2025 annual accounts of
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0797707610
Capital increase of €500,060
18,184 new shares · Gazette deed
Resignation: (director)
Appointment: (director) · Director discharge: · General meeting of 17-07-2024 · Gazette deed
Share issue
Issue of 18,184 shares · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| ImmuneSpec Niel | €3.5m | €883,559 | 74.6% | 5.7 |
| Fishway Leuven | €3.0m | €413,084 | 32.1% | 5.3 |
| MedImprove Mortsel | €2.3m | €616,418 | 13.3% | 3.3 |
| Puxano Ghent | €2.4m | €602,932 | 86.5% | 5.5 |
| CM4Cure Liège | €4.6m | €627,195 | 38.8% | 9.4 |
| XomeXBio Charleroi | €3.5m | €103,430 | 30.2% | 4 |
| Santero Therapeutics Charleroi | €4.2m | €991,461 | 87.5% | 11.9 |
These companies have the same main activity as ImmuneSpec: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €2.3m and €4.6m, founded between 2020 and 2023.
Official details
Source: KBO- Status
- Active since 27-01-2023Normal situation
- Registered office
- 12 active companies are registered at this addressSource: KBO register, as of 14 November 2026.
- Activity
- Research and development on biotechnologyNACE 72101
- Joint committees
- 116Chemical industry
- 207White-collar workers in the chemical industry · annual accounts 2025
- Establishment unit
- 2.341.387.8792845 Niel, since 27-01-2023
- Financial year end
- 31 December
- Peppol
- Reachable since 02-07-2025
Annual accounts 2025
- €3.5m▲ 11.2%
- Employeeson 31-12-2025
- 6▲ 50.0%
- Filing
- Filed on 08-06-2026, 53 days before the end of the filing period
Insights on ImmuneSpec
ImmuneSpec files the abbreviated format. That format states no turnover. The gross margin rose from €51,531 in 2023 to €883,559 in 2025.
In March 2023, three directors stepped down.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about ImmuneSpec
- What is the company number of ImmuneSpec?
- The company number of ImmuneSpec is 0797.707.610. The VAT number is the same number with BE in front: BE 0797.707.610.
- Where is ImmuneSpec based?
- The registered office is at Galileilaan 18, 2845 Niel.Company details
- What does ImmuneSpec do?
- According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
- What is the legal form of ImmuneSpec?
- ImmuneSpec is a private limited company (BV).
- When was ImmuneSpec founded?
- ImmuneSpec was founded on 27-01-2023.
- Is ImmuneSpec still active?
- Yes, ImmuneSpec is an active enterprise in the KBO register.
- How many employees does ImmuneSpec have?
- ImmuneSpec had an average of 5.7 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does ImmuneSpec fall under?
- In its 2025 annual accounts, ImmuneSpec states joint committees 116 (Chemical industry) and 207 (White-collar workers in the chemical industry).
- What is the turnover of ImmuneSpec?
- The turnover in financial year 2025 is ≈ €2.1m. This figure is estimated from the gross margin of €883,559 and 2,135 comparable companies of the same size. It probably lies between €1.3m and €3.6m. It is a rough estimate.
- Is ImmuneSpec profitable?
- In financial year 2025, ImmuneSpec made a loss of €201,723.
- Where can I find the annual accounts of ImmuneSpec?
- ImmuneSpec filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ImmuneSpec due?
- ImmuneSpec must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.